Benitec Biopharma (BNTC) 10-K 2 Sep 22 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Jun. 30, 2022	Aug. 15, 2022	Dec. 31, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-39267
Entity Registrant Name	Benitec Biopharma Inc.
Entity Tax Identification Number	84-4620206
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001808898
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3940 Trust Way
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	510
Local Phone Number	780-0819
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	BNTC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		8,171,690
Entity Public Float			$ 21,383,111
Auditor Name	BAKER TILLY US, LLP
Auditor Firm ID	23
Auditor Location	Campbell, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 4,062	$ 19,769
Restricted Cash	14	15
Trade and other receivables	3	25
Prepaid and other assets	741	799
Total current assets	4,820	20,608
Property and equipment, net	222	375
Deposits	25	9
Other assets	135	185
Right-of-use assets	771	202
Total assets	5,973	21,379
Current liabilities:
Trade and other payables	1,880	880
Accrued employee benefits	400	276
Lease liabilities, current portion	252	213
Total current liabilities	2,532	1,369
Lease liabilities, less current portion	559
Total liabilities	3,091	1,369
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.0001 par value—40,000,000 shares authorized; 8,171,690 shares issued and outstanding at June 30, 2022 and 2021	1	1
Additional paid-in capital	152,453	151,583
Accumulated deficit	(148,327)	(130,119)
Accumulated other comprehensive loss	(1,245)	(1,455)
Total stockholders' equity	2,882	20,010
Total liabilities and stockholders' equity	$ 5,973	$ 21,379

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common Stock Par Value	$ 0.0001	$ 0.0001
Common Stock Shares Authorized	40,000,000	40,000,000
Common Stock, Shares Issued	8,171,690	8,171,690
Common Stock, Shares Outstanding	8,171,690	8,171,690

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenues from customers	$ 73	$ 59
Operating expenses
Royalties and license fees	9	123
Research and development	11,272	7,020
General and administrative	6,646	6,512
Total operating expenses	17,927	13,655
Loss from operations	(17,854)	(13,596)
Other income (loss):
Foreign currency transaction loss	(232)	(333)
Interest expense, net	(32)	(6)
Other income (expense), net	(79)	37
Unrealized gain (loss) on investment	(11)	16
Total other loss, net	(354)	(286)
Net loss	(18,208)	(13,882)
Other comprehensive income (loss):
Unrealized foreign currency translation gain	210	498
Total other comprehensive income	210	498
Total comprehensive loss	$ (17,998)	$ (13,384)
Net loss per share:
Basic	$ (2.23)	$ (3.23)
Diluted	$ (2.23)	$ (3.23)
Weighted-average shares outstanding:
Basic	8,171,690	4,295,416
Diluted	8,171,690	4,295,416

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at the beginning at Jun. 30, 2020	$ 10,238	$ 0	$ 128,827	$ (116,636)	$ (1,953)
Balance at the beginning (In shares) at Jun. 30, 2020		1,108,374
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $3,228	22,519	$ 1	22,518
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $3,228, Shares		6,504,154
Exercise of pre-funded warrants, Shares		559,162
Exercise of pre-funded warrants	3		3
Share-based compensation	634		634
Forfeiture of share-based payments			(399)	399
Foreign currency translation loss (Gain)	498				498
Net loss	(13,882)			(13,882)
Balance at end at Jun. 30, 2021	20,010	$ 1	151,583	(130,119)	(1,455)
Balance at end (In shares) at Jun. 30, 2021		8,171,690
Share-based compensation	870		870
Foreign currency translation loss (Gain)	210				210
Net loss	(18,208)			(18,208)
Balance at end at Jun. 30, 2022	$ 2,882	$ 1	$ 152,453	$ (148,327)	$ (1,245)
Balance at end (In shares) at Jun. 30, 2022		8,171,690

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Jun. 30, 2021 USD ($)
Equity [Abstract]
Payments For Stock Issuance Costs	$ 3,228

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (18,208)	$ (13,882)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization	167	231
Amortization of right-of-use assets	225	193
Unrealized (gain) loss on investment	10	(16)
Share-based compensation expense	870	634
Changes in operating assets and liabilities:
Trade and other receivables	1	28
Prepaid and other assets	62	(4)
Trade and other payables	1,090	55
Accrued employee benefit payable	80	121
Lease liability	(196)	(192)
Net cash used in operating activities	(15,899)	(12,832)
Cash flows from investing activities:
Purchases of property and equipment	(13)	(221)
Net cash used in investing activities	(13)	(221)
Cash flows from financing activities:
Proceeds from issues of shares and pre-funded warrants		25,750
Share issue transaction costs		(3,228)
Net cash provided by financing activities		22,522
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	204	499
Net increase (decrease) in cash, cash equivalents, and restricted cash	(15,708)	9,968
Cash, cash equivalents, and restricted cash at beginning of year	19,784	9,816
Cash, cash equivalents, and restricted cash at end of year	4,076	19,784
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	4,062	19,769
Restricted Cash	14	15
Total cash, cash equivalents, and restricted cash	4,076	19,784
Supplemental disclosure of cash flow information:
Re-measurement of operating lease right-of-use assets and liabilities	$ 794	$ 0

Business

Business	12 Months Ended
	Jun. 30, 2022
Schedule Of Entities In Control [Abstract]
Business	1. Business Benitec Biopharma Inc. (the “Company”) is a corporation formed under the laws of Delaware, United States of America, on November 22, 2019 and listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BNTC”. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (“BBL”). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April 15, 2020. On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company’s business focuses on the development of novel genetic medicines. Our proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. On November 27, 2019, BBL announced its intention to re-domicile from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the re-domiciliation (“the Re-domiciliation”), acquired all BBL shares and BBL became a wholly owned subsidiary of Benitec Biopharma Inc. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL’s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company’s common stock for every three ADSs held. The re-domiciliation was completed on April 15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March 26, 2020 and by the Supreme Court of Queensland on March 30, 2020. In accordance with the U.S. Securities and Exchange Commission’s (“SEC”) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company’s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 ratio and share consolidation as if it occurred on July 1, 2019. The terms the “Company,” “we,” “us,” “our” and similar terms used herein refer (i), prior to the re-domiciliation to BBL, an Australian corporation, and its subsidiaries, and (ii), following the re-domiciliation, to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL). On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. During the year ended June 30, 2021, the Company completed an organization restructure as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. The Company’s fiscal year end is June 30. References to a particular “fiscal year” and the “year ended June 30” are to our fiscal year end June 30 of that calendar year. The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: Principal place of Benitec Biopharma Proprietary Limited (“BBL”) Australia Benitec Australia Proprietary Limited Australia Benitec Limited United Kingdom Benitec, Inc. USA Benitec LLC USA RNAi Therapeutics, Inc. USA Tacere Therapeutics, Inc. USA Benitec IP Holdings, Inc. USA

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of presentation and summary of significant accounting policies	2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation On April 15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon consummation of the Re-domiciliation. As a result, the financial statements included in this report reflect (i) the historical operating results of BBL and subsidiaries prior to the Re-domiciliation; (ii) the combined results of the Company, BBL, and subsidiaries following the completion of the Re-domiciliation; and (iii) the Company’s equity structure for all periods presented . The Company’s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the SEC. Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Principles of Consolidation The consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Use of Estimates The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company’s products and processes and clinical efficacy and safety of the Company’s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Moreover, the current COVID-19 pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the start-up and conduct of the Company’s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company’s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company’s business will depend on future developments that are highly uncertain and cannot be predicted at this time. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency and reporting currency is the United States dollar. BBL’s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive loss.” Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). As of June 30, 2022, and 2021, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: June 30, June 30, Exchange rate on balance sheet dates USD: AUD Exchange Rate 0.6891 0.7506 Average exchange rate for the period USD: AUD Exchange Rate 0.7254 0.7470 Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820, Fair Value Measurements. The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2022, and 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. Restricted cash balances of $14,000 and $15,000 as of June 30, 2022 and June 30, 2021, respectively, secure the Company’s credit cards. Concentrations of Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Trade and Other Receivables As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: Software 3 years Lab equipment 4 years Computer hardware 3 years Leasehold improvements shorter of the lease term or estimated useful lives Impairment of Long-Lived Assets Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Trade and other payables These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. Leases At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. Basic and Diluted Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June 30, 2022 and 2021, there were 845,159 and 809,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. Revenue Recognition The Company recognizes revenue by applying the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606— Revenue from Contracts with Customers Management has also made the judgement that the grant of the license and transfer of associated know-how and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and know-how and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of know-how has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. Licensing revenues Revenue from licensees of the Company’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. Royalties Revenue from licensees of the Company’s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer’s subsequent sales of products occur. Services revenue Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. Research and Development Expense Research and development expenses relate primarily to the cost of conducting clinical and pre-clinical trials. Pre- clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. Equity-based Compensation Expense The Company records share-based compensation in accordance with ASC 718, Stock Compensation recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and non-employee share-based compensation at fair value using the Black-Scholes Option Pricing Model. Income Taxes The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 Accounting for Income Taxes For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss). Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13: Financial Instruments—Credit Losses (Topic 326). Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates Prior Period Reclassification Certain amounts in the prior period have been reclassified to conform with current period presentation.

Liquidity

Liquidity	12 Months Ended
	Jun. 30, 2022
Liquidity [Abstract]
Liquidity	3. Liquidity The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal years ended June 30, 2022 and 2021, the Company had a net loss of $18.2 million and $13.9 million, respectively, and net cash used in operations of $15.9 million and $12.8 million, respectively. As of June 30, 2022, the Company had $4.1 million in cash and cash equivalents. The Company has incurred operating losses and negative cash flows from operations since inception, except for the year ended June 30, 2019. The Company has concluded that substantial doubt exists about its ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future.

Revenue

Revenue	12 Months Ended
	Jun. 30, 2022
Revenues [Abstract]
Revenue	4. Revenue Revenues from customers (US$’000) Year Year Licensing revenue $ 73 $ 59 Total $ 73 $ 59 The Company recognized licensing revenue over time as the performance obligations were satisfied.

Cash, cash equivalents, and res

Cash, cash equivalents, and restricted cash	12 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash, cash equivalents, and restricted cash	5. Cash, cash equivalents, and restricted cash (US$’000) June 30, June 30, Cash at b $ 4,062 $ 19,769 Restricted cash 14 15 Total $ 4,076 $ 19,784

Prepaid and Other assets

Prepaid and Other assets	12 Months Ended
	Jun. 30, 2022
Other Assets [Abstract]
Prepaid and Other assets	6. Prepaid and other assets (US$’000) June 30, 2022 June 30, 2021 Prepaid expenses $ 871 $ 967 Market value of listed shares 5 17 Total other assets 876 984 Less: non-current portion (135 ) (185 ) Current portion $ 741 $ 799

Property and equipment, net

Property and equipment, net	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment, Net [Abstract]
Property and equipment, net	7. Property and equipment, net (US$’000) June 30, 2022 June 30, 2021 Software $ 6 $ 14 Lab equipment 1,343 1,329 Computer hardware 31 26 Leasehold improvements 24 24 Total property and equipment, gross 1,404 1,393 Accumulated depreciation and amortization (1,182 ) (1,018 ) Total property and equipment, net $ 222 $ 375 Depreciation and amortization expense was $167,000 and $231,000 for the years ended June 30, 2022 and 2021, respectively.

Trade and other payables

Trade and other payables	12 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Trade and other payables	8. Trade and other payables (US$’000) June 30, 2022 June 30, 2021 Trade payable $ 422 $ 274 Accrued License Fees 120 140 Accrued professional fees 131 36 Accrued OPMD project costs 1,089 279 Accrued consultant fees 47 36 Other payables 71 115 Total $ 1,880 $ 880

Leases

Leases	12 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	9. Leases On July 1, 2019, the Company adopted ASC 842, Leases The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes, and other operating expenses. The Company’s lease does not contain any residual value guarantees or material restrictive covenants. The tables below show the changes during the year ended June 30, 2022 and 2021: (US$’000) Operating Initial measurement at July 1, 2020 $ 395 Amortization of right of use asset (193 ) Balance at June 30, 2021 202 Re-measurement during the period 794 Amortization of right of use asset (225 ) Operating lease right-of-use asset at June 30, 2022 $ 771 (US$’000) Operating Initial measurement at July 1, 2020 $ 405 Principal payments on operating lease liabilities (192 ) Operating lease liabilities at June 30, 2021 213 Re-measurement during the period 794 Principal payments on operating lease liabilities (196 ) Operating lease liabilities at June 30, 2022 811 Less: non-current portion 559 Current portion at June 30, 202 2 $ 252 As of June 30, 2022, the Company’s operating lease has a remaining lease term of 2.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: (US$’000) June 30, 2023 285 2024 295 2025 291 Total operating lease payments 871 Less imputed interest (60 ) Present value of operating lease liabilities $ 811 For the fiscal years ended June 30, 2022 and 2021, total lease expense under operating leases was approximately $260,000 and $208,000, respectively, and was recorded in general and administrative expenses.

Stockholders' equity

Stockholders' equity	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' equity	10. Stockholders’ equity Common Stock On October 6, 2020, the Company announced the closing of an underwritten public offering 2,666,644 shares of its common stock at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the offering price of $3.10 per share.​​​​​​​ On April 30, 2021, the Company announced the closing of an underwritten public offering of 3,036,366 shares of its common stock at a price to the public of $4.25 per share. The Company also announced that the underwriter exercised the over-allotment option to purchase 317,274 additional shares of its common stock at the offering price of $4.25 per share. Warrants On December 6, 2019, the Investors were issued 4 Purchase Warrants that were exercisable into 214,190 fully paid shares of common stock should the Purchase Warrants be exercised in full (“Purchase Warrants”). The exercise price for the Purchase Warrants is US$10.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth On October 6, 2020, the Company announced the closing of an underwritten public offering of 559,162 shares of common stock underlying pre-funded warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share (“Pre-Funded Warrants”). All 559,162 Pre-Funded Warrants issued had been exercised as of June 30, 2021. The activity related to warrants during for the fiscal years ended June 30, 2022 and 2021, is summarized as follows: Common Weighted- Outstanding and exercisable at July 1, 2020 145,424 29.48 Granted 559,162 3.09 Exercised (559,162 ) 3.10 Forfeited (38,329 ) 82.50 Outstanding and exercisable at June 30, 2021 107,095 $ 10.50 Outstanding and exercisable at June 30, 2022 107,095 $ 10.50 Equity Incentive Plan Employee Share Option Plan Upon the Re-domiciliation, the Company assumed BBL’s obligations with respect to the settlement of options that were issued by BBL prior to the Re-domiciliation pursuant to the Benitec Officers’ and Employees’ Share Option Plan (the “Plan”). This includes the Company’s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances . Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the employee has 12 months to exercise their options, or the options are cancelled. After the Re-domiciliation, no new options have been or will be issued under the Plan. Equity and Incentive Compensation Plan On December 9, 2020, the Company’s stockholders approved the Company’s 2020 Equity and Incentive Compensation Plan (the “2020 Plan”). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company’s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of one-third on each anniversary of the applicable grant date over three years. Non-employee director options vest in increments of one-third on the day prior to each of the Company’s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan), the option holder generally has 12 months to exercise their vested options, or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan), the option holder generally has 90 days to exercise their vested options, or the options are cancelled. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options will immediately vest as of immediately prior to the Change in Control. On December 8, 2021, the Company’s stockholders approved an amendment to the 2020 Plan, which increased the number of shares of the Company’s common stock reserved under the 2020 Plan. For the fiscal year ended June 30, 2022, our named executive officers (“NEO’s”) were not granted any equity incentive awards. Equity Awards The activity related to equity awards, which comprised of stock options during the fiscal years ended June 30, 2022 and 2021, respectively, is summarized as follows: Stock Weighted- Weighted- Aggregate Outstanding at July 1, 2020 70,154 60.42 2.89 years — Exercisable at July 1, 2020 41,829 69.81 2.59 years — Granted 640,320 3.29 Forfeited (8,410 ) 153.79 Outstanding at June 30, 2021 702,064 7.16 8.07 years — Exercisable at June 30, 2021 54,158 $ 47.90 2.09 years $ — Granted 36,000 2.99 9.45 years $ — Outstanding at June 30, 2022 738,064 6.95 7.18 years $ — Exercisable at June 30, 2022 275,174 13.16 6.19 years $ — Equity-based Compensation Expense The weighted-average grant-date fair value of stock options granted during the years ended June 30, 2022 and June 30, 2021 was $2.60 and $2.68, respectively. The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option- pricing model with the following assumptions: Fiscal Year Ended 2022 2021 Expected volatility 122.1 % 112.0-127.4 % Expected term 6 years 3.5-6 years Risk-free interest rate 1.36 % 0.44-0.55 % Expected dividend yield — % — % Expected Volatility. Expected Risk-free Interest Rate. Expected Dividend Yield. In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. Share-Based Compensation Expense The classification of share-based compensation expense for the years ended: (US$’000) June 30, 2022 2021 Research and development $ 257 $ 212 General and administrative 613 422 Total share-based compensation expense $ 870 $ 634 As of June 30, 2022, and 2021, there was $522,000 and $1,266,000, respectively, of unrecognized share-based compensation expense related to stock options granted under the Plan and 2020 Plan.

Income taxes

Income taxes	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income taxes	11. Income taxes Loss before provision for income taxes consisted of the following: (US$’000) Year Ended June 30, 2022 2021 United States $ (17,369 ) $ 7,911 International (839 ) (5,971 ) Total $ (18,208 ) $ (13,882 ) The tax effects of significant items comprising the Company’s deferred taxes are as follows: (US$’000) June 30, 2022 2021 Deferred tax assets: Net operating losses $ 17,348 $ 15,902 Other 348 230 Lease liability 170 45 Share-based compensation 205 88 Intangible assets 250 212 Gross deferred tax assets 18,321 16,477 Less valuation allowance (17,965 ) (16,223 ) Deferred tax liabilities: Right-of-use assets (162 ) (42 ) Fixed assets (43 ) (76 ) Prepaid expenses (151 ) (136 ) Total deferred tax liabilities (356 ) (254 ) Net deferred taxes $ — $ — ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. As of June 30, 2022, and 2021, the Company established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. The valuation allowance increased $1,742 (US$’000) Amount Expiration Net operating losses, federal (post-December 31, 2017) $ 25,597 Do not expire Net operating losses, state 4,632 2031-2034 Net operating losses, Australia 46,596 Do not expire The effective rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: Year Ended 2022 2021 Statutory rate 21.00 % 21.00 % Permanent differences (0.22 %) (8.9 %) Share-based payments (0.36 %) (0.32 %) Change in valuation allowance (20.55 %) (13.9 %) Foreign tax rate differential 0.13 % 2.12 % Total (0.00 %) (0.00 %) The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company’s tax returns for the tax years 2014 through 2021 are open and are subject to examination by federal taxing authorities and the Company’s tax returns for tax years 2011 through 2021 are subject to examination by state taxing authorities. The Company is not currently undergoing a tax audit in any federal, state or Australian jurisdiction. The Company does not have any uncertain tax benefits “(UTBs)” as of June 30, 2022 and does not expect its UTBs to change significantly over the next 12 months. Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. Under Australian income tax legislation, losses can be utilized by the Company if it satisfies firstly the Continuity of Ownership Test (“COT”) or if failing that, the Similar Business Test (“SBT”). Broadly, the COT requires a company to show that it maintained continuity of majority beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The SBT requires a company to demonstrate that a “similar business” has been maintained from the time when the COT is failed and throughout the period until the end of the income year that the losses are being recouped. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five-year net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation of 80% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is no material impact to the income tax provision for the fiscal year ended June 30, 2022. On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses (NOL) and limits the use of research tax credits for 2020, 2021 and 2022, respectively. However, on February 9, 2022, Governor Gavin Newsom signed CA SB 113 (SB 113) into law. The legislation shortens the suspension period for deducting NOL. The suspension of deductions of California NOLs applied to California taxpayers with net business income of $ million or more for tax years beginning on or after , and before . The Company evaluated the impact of the new legislation and determined that it did not materially impact the Company’s income tax provision for the fiscal year ended June 30, 2022.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	12. Commitments and contingencies Contract commitments The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. There are no contingent liabilities as of June 30, 2022 and 2021, respectively. See Note 9 above for lease commitments.

Related party transactions

Related party transactions	12 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related party transactions	13. Related party transactions During the year ended June 30, 2022, the Company had entered into related party transactions with Francis Abourizk Lightowlers for legal fees totaling $1 thousand. Peter Francis, a non-executive director of the Company is a partner at Francis Abourizk Lightowlers.

Loss per share

Loss per share	12 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Loss per share	14. Loss per share Year Ended June 30, 2022 2021 Net loss attributable to common stockholders (US$’000) ($ 18,208 ) ($ 13,882 ) Weighted average number of shares used in calculating basic and diluted earnings per share 8,171,690 4,295,416 Basic and diluted loss per share ($ 2.23 ) ($ 3.23 ) Outstanding warrants and options amounting to 845,159 and 809,159 to acquire common stock are considered anti-dilutive for the fiscal years ended June 30, 2022 and June 30, 2021.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation On April 15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon consummation of the Re-domiciliation. As a result, the financial statements included in this report reflect (i) the historical operating results of BBL and subsidiaries prior to the Re-domiciliation; (ii) the combined results of the Company, BBL, and subsidiaries following the completion of the Re-domiciliation; and (iii) the Company’s equity structure for all periods presented . The Company’s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the SEC. Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.
Use of Estimates	Use of Estimates The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company’s products and processes and clinical efficacy and safety of the Company’s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Moreover, the current COVID-19 pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the start-up and conduct of the Company’s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company’s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company’s business will depend on future developments that are highly uncertain and cannot be predicted at this time.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency and reporting currency is the United States dollar. BBL’s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive loss.” Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). As of June 30, 2022, and 2021, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: June 30, June 30, Exchange rate on balance sheet dates USD: AUD Exchange Rate 0.6891 0.7506 Average exchange rate for the period USD: AUD Exchange Rate 0.7254 0.7470
Fair Value Measurements	Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820, Fair Value Measurements. The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2022, and 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. Restricted cash balances of $14,000 and $15,000 as of June 30, 2022 and June 30, 2021, respectively, secure the Company’s credit cards.
Concentrations of Risk	Concentrations of Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Trade and Other Receivables	Trade and Other Receivables As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: Software 3 years Lab equipment 4 years Computer hardware 3 years Leasehold improvements shorter of the lease term or estimated useful lives
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Trade and other payables	Trade and other payables These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.
Leases	Leases At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June 30, 2022 and 2021, there were 845,159 and 809,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive.
Revenue Recognition	Revenue Recognition The Company recognizes revenue by applying the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606— Revenue from Contracts with Customers Management has also made the judgement that the grant of the license and transfer of associated know-how and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and know-how and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of know-how has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. Licensing revenues Revenue from licensees of the Company’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. Royalties Revenue from licensees of the Company’s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer’s subsequent sales of products occur. Services revenue Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed.
Research and Development Expense	Research and Development Expense Research and development expenses relate primarily to the cost of conducting clinical and pre-clinical trials. Pre- clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred.
Equity-based Compensation Expense	Equity-based Compensation Expense The Company records share-based compensation in accordance with ASC 718, Stock Compensation
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 Accounting for Income Taxes For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13: Financial Instruments—Credit Losses (Topic 326). Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates
Prior Period Reclassification	Prior Period Reclassification Certain amounts in the prior period have been reclassified to conform with current period presentation.

Business (Tables)

Business (Tables)	12 Months Ended
	Jun. 30, 2022
Schedule Of Entities In Control [Abstract]
Summary of entities in control	The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: Principal place of Benitec Biopharma Proprietary Limited (“BBL”) Australia Benitec Australia Proprietary Limited Australia Benitec Limited United Kingdom Benitec, Inc. USA Benitec LLC USA RNAi Therapeutics, Inc. USA Tacere Therapeutics, Inc. USA Benitec IP Holdings, Inc. USA

Basis of presentation and sum_3

Basis of presentation and summary of significant accounting policies (Tables)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of foreign currency translation and other comprehensive income (loss)	As of June 30, 2022, and 2021, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: June 30, June 30, Exchange rate on balance sheet dates USD: AUD Exchange Rate 0.6891 0.7506 Average exchange rate for the period USD: AUD Exchange Rate 0.7254 0.7470
Summary of property and equipment	Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: Software 3 years Lab equipment 4 years Computer hardware 3 years Leasehold improvements shorter of the lease term or estimated useful lives

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2022
Revenues [Abstract]
Summary of revenue from customers	Revenues from customers (US$’000) Year Year Licensing revenue $ 73 $ 59 Total $ 73 $ 59

Cash, cash equivalents, and r_2

Cash, cash equivalents, and restricted cash (Tables)	12 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents	(US$’000) June 30, June 30, Cash at b $ 4,062 $ 19,769 Restricted cash 14 15 Total $ 4,076 $ 19,784

Prepaid and Other assets (Table

Prepaid and Other assets (Tables)	12 Months Ended
	Jun. 30, 2022
Other Assets [Abstract]
Summary of other current assets	(US$’000) June 30, 2022 June 30, 2021 Prepaid expenses $ 871 $ 967 Market value of listed shares 5 17 Total other assets 876 984 Less: non-current portion (135 ) (185 ) Current portion $ 741 $ 799

Property and equipment, net (Ta

Property and equipment, net (Tables)	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment, Net [Abstract]
Summary of property and equipment net	(US$’000) June 30, 2022 June 30, 2021 Software $ 6 $ 14 Lab equipment 1,343 1,329 Computer hardware 31 26 Leasehold improvements 24 24 Total property and equipment, gross 1,404 1,393 Accumulated depreciation and amortization (1,182 ) (1,018 ) Total property and equipment, net $ 222 $ 375

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Summary of trade and other payables	(US$’000) June 30, 2022 June 30, 2021 Trade payable $ 422 $ 274 Accrued License Fees 120 140 Accrued professional fees 131 36 Accrued OPMD project costs 1,089 279 Accrued consultant fees 47 36 Other payables 71 115 Total $ 1,880 $ 880

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Summary of supplemental balance sheet information related to leases	The tables below show the changes during the year ended June 30, 2022 and 2021: (US$’000) Operating Initial measurement at July 1, 2020 $ 395 Amortization of right of use asset (193 ) Balance at June 30, 2021 202 Re-measurement during the period 794 Amortization of right of use asset (225 ) Operating lease right-of-use asset at June 30, 2022 $ 771 (US$’000) Operating Initial measurement at July 1, 2020 $ 405 Principal payments on operating lease liabilities (192 ) Operating lease liabilities at June 30, 2021 213 Re-measurement during the period 794 Principal payments on operating lease liabilities (196 ) Operating lease liabilities at June 30, 2022 811 Less: non-current portion 559 Current portion at June 30, 202 2 $ 252
Summary of maturities of the operating lease liabilities	As of June 30, 2022, the Company’s operating lease has a remaining lease term of 2.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: (US$’000) June 30, 2023 285 2024 295 2025 291 Total operating lease payments 871 Less imputed interest (60 ) Present value of operating lease liabilities $ 811

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of warrants or rights	The activity related to warrants during for the fiscal years ended June 30, 2022 and 2021, is summarized as follows: Common Weighted- Outstanding and exercisable at July 1, 2020 145,424 29.48 Granted 559,162 3.09 Exercised (559,162 ) 3.10 Forfeited (38,329 ) 82.50 Outstanding and exercisable at June 30, 2021 107,095 $ 10.50 Outstanding and exercisable at June 30, 2022 107,095 $ 10.50
Schedule of equity awards	The activity related to equity awards, which comprised of stock options during the fiscal years ended June 30, 2022 and 2021, respectively, is summarized as follows: Stock Weighted- Weighted- Aggregate Outstanding at July 1, 2020 70,154 60.42 2.89 years — Exercisable at July 1, 2020 41,829 69.81 2.59 years — Granted 640,320 3.29 Forfeited (8,410 ) 153.79 Outstanding at June 30, 2021 702,064 7.16 8.07 years — Exercisable at June 30, 2021 54,158 $ 47.90 2.09 years $ — Granted 36,000 2.99 9.45 years $ — Outstanding at June 30, 2022 738,064 6.95 7.18 years $ — Exercisable at June 30, 2022 275,174 13.16 6.19 years $ —
Schedule of equity-based compensation expense	The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option- pricing model with the following assumptions: Fiscal Year Ended 2022 2021 Expected volatility 122.1 % 112.0-127.4 % Expected term 6 years 3.5-6 years Risk-free interest rate 1.36 % 0.44-0.55 % Expected dividend yield — % — %
Schedule of share-basedcompensation expense	The classification of share-based compensation expense for the years ended: (US$’000) June 30, 2022 2021 Research and development $ 257 $ 212 General and administrative 613 422 Total share-based compensation expense $ 870 $ 634

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Summary of income (loss) before provision for income taxes	Loss before provision for income taxes consisted of the following: (US$’000) Year Ended June 30, 2022 2021 United States $ (17,369 ) $ 7,911 International (839 ) (5,971 ) Total $ (18,208 ) $ (13,882 )
Summary of company's deferred taxes	The tax effects of significant items comprising the Company’s deferred taxes are as follows: (US$’000) June 30, 2022 2021 Deferred tax assets: Net operating losses $ 17,348 $ 15,902 Other 348 230 Lease liability 170 45 Share-based compensation 205 88 Intangible assets 250 212 Gross deferred tax assets 18,321 16,477 Less valuation allowance (17,965 ) (16,223 ) Deferred tax liabilities: Right-of-use assets (162 ) (42 ) Fixed assets (43 ) (76 ) Prepaid expenses (151 ) (136 ) Total deferred tax liabilities (356 ) (254 ) Net deferred taxes $ — $ —
Summary of net operating losses and tax credit carryforwards	Net operating losses and tax credit carryforwards as of June 30, 2022 are as follows: (US$’000) Amount Expiration Net operating losses, federal (post-December 31, 2017) $ 25,597 Do not expire Net operating losses, state 4,632 2031-2034 Net operating losses, Australia 46,596 Do not expire
Summary reconciliation of effective rate of the company's provision (benefit) for income taxes	The effective rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: Year Ended 2022 2021 Statutory rate 21.00 % 21.00 % Permanent differences (0.22 %) (8.9 %) Share-based payments (0.36 %) (0.32 %) Change in valuation allowance (20.55 %) (13.9 %) Foreign tax rate differential 0.13 % 2.12 % Total (0.00 %) (0.00 %)

Loss per share (Tables)

Loss per share (Tables)	12 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Summary of Loss per share	Year Ended June 30, 2022 2021 Net loss attributable to common stockholders (US$’000) ($ 18,208 ) ($ 13,882 ) Weighted average number of shares used in calculating basic and diluted earnings per share 8,171,690 4,295,416 Basic and diluted loss per share ($ 2.23 ) ($ 3.23 )

Business - Summary of entities

Business - Summary of entities in control (Detail)	12 Months Ended
	Jun. 30, 2022
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	DE
Benitec Biopharma Proprietary Limited ("BBL") [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	C3
Benitec Australia Proprietary Limited [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	C3
Benitec Limited [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X0
Benitec, Inc. [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Benitec LLC [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
RNAi Therapeutics, Inc. [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Tacere Therapeutics, Inc. [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Benitec IP Holdings, Inc.[Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1

Business - Additional informati

Business - Additional information (Detail)		12 Months Ended
	Nov. 27, 2019	Jun. 30, 2022
Schedule Of Entities In Control [Abstract]
Entity Incorporation Date Of Incorporation		Nov. 22, 2019
Common Stock, Shares, Re-domiciliation Description	one Benitec Biopharma Inc. share for every 300 BBL shares

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Accounting Policies [Abstract]
Exchange rate on balance sheet dates, USD: AUD Exchange Rate	0.6891	0.7506
Average exchange rate for the period, USD: AUD Exchange Rate	0.7254	0.747

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)	12 Months Ended
	Jun. 30, 2022
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	shorter of the lease term or estimated useful lives

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from the computation of earnings per share	845,159	809,159
Restricted Cash	$ 14,000	$ 15,000
Fair Value, Recurring [Member]
Summary Of Significant Accounting Policies [Line Items]
Financial assets at fair value	0	0
Financial liabilities at fair value	$ 0	$ 0

Liquidity - Additional informat

Liquidity - Additional information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Liquidity [Abstract]
Net loss	$ (18,208)	$ (13,882)
Net cash used in provided by operations	(15,899)	(12,832)
Cash and cash equivalents	$ 4,062	$ 19,769

Revenue - Summary of revenue fr

Revenue - Summary of revenue from customers (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue from External Customer [Line Items]
Revenues from customers	$ 73	$ 59
Licensing revenue [Member]
Revenue from External Customer [Line Items]
Revenues from customers	$ 73	$ 59

Cash, cash equivalents, and r_3

Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash at bank	$ 4,062	$ 19,769
Restricted Cash	14	15
Total cash, cash equivalents, and restricted cash	$ 4,076	$ 19,784

Prepaid and Other assets - Summ

Prepaid and Other assets - Summary of other current assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Other Assets [Abstract]
Prepaid expenses	$ 871	$ 967
Market value of listed shares	5	17
Total other assets	876	984
Less: non-current portion	(135)	(185)
Current portion	$ 741	$ 799

Property and equipment, net - S

Property and equipment, net - Summary of property and equipment net (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 1,404	$ 1,393
Accumulated depreciation and amortization	(1,182)	(1,018)
Total property and equipment, net	222	375
Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	6	14
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,343	1,329
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	31	26
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 24	$ 24

Property and equipment, net - A

Property and equipment, net - Additional information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment, Net [Abstract]
Depreciation	$ 167,000	$ 231,000

Trade and other payables- Summa

Trade and other payables- Summary of trade and other payables (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Payables and Accruals [Abstract]
Trade payable	$ 422	$ 274
Accrued License Fees	120	140
Accrued professional fees	131	36
Accrued OPMD project costs	1,089	279
Accrued consultant fees	47	36
Other payables	71	115
Total	$ 1,880	$ 880

Leases - Summary of supplementa

Leases - Summary of supplemental balance sheet information related to leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Initial measurement at July 1, 2020	$ 202
Amortization of right of use asset	(225)	$ (193)
Re-measurement during the period	794
Ending Balance	771	202
Initial measurement at July 1, 2020	213
Principal payments on operating lease liabilities	(196)	(192)
Re-measurement during the period	794
Operating lease liabilities	811	213
Less: non-current portion	559
Current portion at June 30, 2021	$ 252	213
Accounting Standards Update 2016-02 [Member]
Initial measurement at July 1, 2020		395
Initial measurement at July 1, 2020		$ 405

Leases - Summary of maturities

Leases - Summary of maturities of the operating lease liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
2023	$ 285
2024	295
2025	291
Total operating lease payments	871
Less imputed interest	(60)
Present value of operating lease liabilities	$ 811	$ 213

Leases - Additional information

Leases - Additional information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating lease has a remaining lease term	2 years 11 months 15 days
Operating lease discount rate	4.67%
General and Administrative Expense [Member]
Operating lease expense	$ 260,000	$ 208,000

Stockholders' equity - Schedule

Stockholders' equity - Schedule of warrants or rights (Detail)	12 Months Ended
	Jun. 30, 2021 $ / shares shares
Equity [Abstract]
Outstanding, beginning of period | shares	145,424
Granted | shares	559,162
Exercised | shares	(559,162)
Cashless exercise | shares	(38,329)
Outstanding, ending of period | shares	107,095
Exercise price of class of warrants or rights outstanding | $ / shares	$ 29.48
Granted | $ / shares	3.09
Exercised | $ / shares	3.1
Cashless exercise | $ / shares	82.5
Exercise price of class of warrants or rights outstanding and excercisable | $ / shares	$ 10.5

Stockholders' equity - Schedu_2

Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options,Outstanding, beginning of period	702,064	70,154
Stock Options, Exercisable, beginning of period	54,158	41,829
Stock Options, Granted	36,000	640,320
Stock Options, Forfeited		(8,410)
Stock Options, Outstanding, end of period	738,064	702,064	70,154
Stock Options, Exercisable, end of period	275,174	54,158	41,829
Exercise price, beginning of period	$ 7.16	$ 60.42
Weighted-average Exercise Price, Exercisable, beginning of period	47.9	69.81
Weighted-average Exercise Price, Granted	2.99	3.29
Weighted-average Exercise Price, Forfeited		153.79
Weighted-average Exercise Price, Exercise price, end of period	6.95	7.16	$ 60.42
Weighted-average Exercise Price, Exercisable, end of period	$ 13.16	$ 47.9	$ 69.81
Weighted-average Remaining Contractual Term, Outstanding	7 years 2 months 4 days	8 years 25 days	2 years 10 months 20 days
Weighted-average Remaining Contractual Term, Exercisable	6 years 2 months 8 days	2 years 1 month 2 days	2 years 7 months 2 days
Weighted-average Remaining Contractual Term, Granted	9 years 5 months 12 days

Stockholders' equity - Summary

Stockholders' equity - Summary of equity-based compensation expense (Detail)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, Minimum	122.10%	112%
Expected volatility, Maximum		127.40%
Expected term	6 years
Risk-free interest rate, Minimum	1.36%	0.44%
Risk-free interest rate, Maximum		0.55%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		6 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		3 years 6 months

Stockholders' equity - Summar_2

Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based compensation expense	$ 870	$ 634
Research and development [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based compensation expense	257	212
General and administrative [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based compensation expense	$ 613	$ 422

Stockholders' equity - Addition

Stockholders' equity - Additional information (Detail)				6 Months Ended	12 Months Ended
	Apr. 30, 2021 $ / shares shares	Oct. 06, 2020 $ / shares shares	Apr. 22, 2020 shares	Dec. 31, 2020 shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Dec. 06, 2019 shares $ / shares
Unrecognised share based compensation expense | $					$ 522,000	$ 1,266,000
Term of warrants							5 years
weighted-average grant-date fair value of stock options granted | $ / shares					$ 2.6	$ 2.68
Common Stock [Member]
Warrants convertible into shares of common stock on exercise			107,095
Cashless exercise of purchase warrants (In shares)			37,417		37,417	37,417
Purchase Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 10.5
Number of series of warrants issued							4
Expiry date of warrants							Dec. 06, 2024
Warrants convertible into shares of common stock on exercise							214,190
IPO [Member]
Sale of Stock, Number of Shares Issued in Transaction		2,666,644
Sale of stock issue price per share | $ / shares		$ 3.1
Over-Allotment Option [Member]
Sale of Stock, Number of Shares Issued in Transaction	317,274	483,870
Sale of stock issue price per share | $ / shares	$ 4.25	$ 3.1
Pre-funded warrants [Member]
Sale of Stock, Number of Shares Issued in Transaction	3,036,366			559,162
Sale of stock issue price per share | $ / shares	$ 4.25	3.09
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.01
Number of Warranrs exercised						559,162

Income taxes - Summary of incom

Income taxes - Summary of income (loss) before provision for income taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
United States	$ (17,369)	$ 7,911
International	(839)	(5,971)
Net loss	$ (18,208)	$ (13,882)

Income taxes - Summary of compa

Income taxes - Summary of company's deferred taxes (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Deferred tax assets:
Net operating losses	$ 17,348	$ 15,902
Other	348	230
Lease liability	170	45
Share-based compensation	205	88
Intangible assets	250	212
Gross deferred tax assets	18,321	16,477
Less valuation allowance	(17,965)	(16,223)
Deferred tax liabilities:
Right-of-use assets	(162)	(42)
Fixed assets	(43)	(76)
Prepaid expenses	(151)	(136)
Total deferred tax liabilities	(356)	(254)
Net deferred taxes	$ 0	$ 0

Income taxes - Summary of net o

Income taxes - Summary of net operating losses and tax credit carryforwards (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Foreign Tax Authority [Member]
Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]
Net operating losses	$ 46,596
Operating loss carryforwards, expiration years	Do not expire
NOL From Two Thousand Eighteen [Member] | Domestic Tax Authority [Member]
Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]
Net operating losses	$ 25,597
Operating loss carryforwards, expiration years	Do not expire
NOL pre January One Two Thousand Eighteen [Member] | State and Local Jurisdiction [Member]
Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]
Net operating losses	$ 4,632
NOL pre January One Two Thousand Eighteen [Member] | State and Local Jurisdiction [Member] | Year Two Thousand And Thirty Four [Member]
Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]
Year of expiry of operating losses carry forwards	2034
NOL pre January One Two Thousand Eighteen [Member] | State and Local Jurisdiction [Member] | Year Two Thousand And Thirty One [Member]
Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]
Year of expiry of operating losses carry forwards	2031

Income taxes - Summary reconcil

Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Statutory rate	21%	21%
Permanent differences	(0.22%)	(8.90%)
Share-based payments	(0.36%)	(0.32%)
Change in valuation allowance	(20.55%)	(13.90%)
Foreign tax rate differential	0.13%	2.12%
Total	0%	0%

Income taxes - Additional infor

Income taxes - Additional information (Detail) - USD ($)		12 Months Ended
	Feb. 09, 2022	Jun. 30, 2022
Income Tax Disclosure [Line Items]
Deferred tax assets increase in valuation allowance during the period		$ 1,742
Uncertain tax benefits		0
Expected change in unrecognised tax benefits in the next twelve months		$ 0
Coronavirus Aid Relief And Economic Security Act [Member]
Income Tax Disclosure [Line Items]
Number of years of certain operating losses that can be carried back		5 years
Income tax expense benefit		$ 0
California Assembly Bill Eighty Five [Member]
Income Tax Disclosure [Line Items]
Income tax expense benefit		$ 0
Suspension Of Annual Deduction Limitation [Member] | Coronavirus Aid Relief And Economic Security Act [Member]
Income Tax Disclosure [Line Items]
Percentage of annual Taxable income eligible for deduction		80%
Internal Revenue Service (IRS) [Member] | Minimum [Member]
Income Tax Disclosure [Line Items]
Percentage of total owneship control to be maintained by the current shareholders for availing operating loss carry forwards		50%
Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards		3 years
Beginning on or After January 1, 2020, and Before January 1, 2023 [Member] | California Franchise Tax Board [Member] | Applicability of Suspension of Deductions of California NOLs [Member] | SB 113 [Member]
Income Tax Disclosure [Line Items]
Minimum net business income	$ 1,000,000
Domestic Tax Authority [Member] | Tax Year 2014 [Member]
Income Tax Disclosure [Line Items]
Tax year subject to examination		2014
Domestic Tax Authority [Member] | Tax Year 2019 [Member]
Income Tax Disclosure [Line Items]
Tax year subject to examination		2021
State and Local Jurisdiction [Member] | Tax Year 2019 [Member]
Income Tax Disclosure [Line Items]
Tax year subject to examination		2021
State and Local Jurisdiction [Member] | Tax Year 2011 [Member]
Income Tax Disclosure [Line Items]
Tax year subject to examination		2011

Commitments and contingencies -

Commitments and contingencies - Additional information (Detail) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Commitments And Contingencies Disclosure [Line Items]
Contingent liabilities

Related party transactions - Ad

Related party transactions - Additional information (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Francis Abourizk Lightowlers [Member]
Related Party Transaction [Line Items]
Legal fees	$ 1

Loss per share - Summary of Los

Loss per share - Summary of Loss per share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ 18,208	$ 13,882
Weighted average number of shares used in calculating basic earnings per share	8,171,690	4,295,416
Basic loss per share	$ 2.23	$ 3.23
Weighted average number of shares used in calculating diluted earnings per share	8,171,690	4,295,416
Diluted loss per share	$ 2.23	$ 3.23

Loss per share - Additional Inf

Loss per share - Additional Information (Detail) - shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive securities excluded from the computation of earnings per share	845,159	809,159
Warrant [Member]
Antidilutive securities excluded from the computation of earnings per share	845,159	845,159
Employee Stock Option [Member]
Antidilutive securities excluded from the computation of earnings per share	809,159	809,159